Roche launches VENTANA PD-L1 (SP142) Assay in CE markets as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq
- This launch represents an important step in Roche’s personalised healthcare strategy to fit treatments to patients who can benefit most from a specific medicine
- Each year 300,000 patients around the world are diagnosed with triple-negative breast cancer, an aggressive disease with limited treatment options1,2
- VENTANA PD-L1 (SP142) Assay helps identify triple-negative breast cancer patients most likely to benefit from treatment with Tecentriq plus chemotherapy
Basel, 29 August 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the expanded use of the VENTANA PD-L1 (SP142) Assay3,4 in triple-negative breast cancer (TNBC) for patients living in CE (Conformité Européene) markets where the Roche cancer immunotherapy medicine Tecentriq® is approved. It is the first companion diagnostic to aid in identifying triple-negative breast cancer patients eligible for treatment with Tecentriq (atezolizumab)5 plus chemotherapy (nab-paclitaxel).6 Assessment of PD-L1 biomarker status on tumour-infiltrating immune cells with the assay is essential for identifying those patients most likely to benefit from the treatment.
Today’s announcement follows the U.S. Food and Drug Administration approval of the assay in March 2019 as the first companion diagnostic to identify triple-negative breast cancer patients eligible for the Tecentriq combination. A diagnosis of triple-negative breast cancer means that the three most common proteins associated with breast cancer growth – estrogen receptor, progesterone receptor and HER2/neu – are not expressed on the tumour.
“Until recently, the only treatment option for metastatic triple-negative breast cancer patients was chemotherapy,” said Thomas Schinecker, Head of Roche Diagnostics. “With our expanding menu of companion diagnostics and targeted cancer immunotherapies, Roche is proud to continue to deliver on our mission to make personalised healthcare a global reality, ensuring the right treatment for the right patient at the right time.”
The VENTANA PD-L1 (SP142) Assay was developed to enhance visual contrast of tumour-infiltrating immune cell staining. In triple-negative breast cancer, PD-L1 is primarily expressed on tumour-infiltrating immune cells rather than on tumour cells themselves.7
Launched in 2016, the VENTANA PD-L1 (SP142) Assay is the primary diagnostic assay within the Tecentriq clinical development program and was used to enroll and stratify patients in Tecentriq clinical trials. It was the enrollment assay used in the IMpassion130 trial, the first positive phase III immunotherapy regimen study in triple-negative breast cancer. The assay was the first to evaluate patient PD-L1 biomarker status using immune cell staining and scoring within the tumour microenvironment.8
About the VENTANA PD-L1 (SP142) Assay
The VENTANA PD-L1 (SP142) Assay is available on the fully automated BenchMark IHC/ISH series instruments and uses the OptiView DAB IHC Detection Kit with OptiView Amplification Kit. The VENTANA PD-L1 (SP142) Assay performs specific staining of tumour cells and immune cells. The assay was previously approved by the FDA and CE marked for use as a companion diagnostic in urothelial carcinoma (UC)5 and as a predictive assay in non-small cell lung cancer (NSCLC) with Tecentriq. See the Tecentriq product label for more information on PD-L1 expression levels in therapeutic guidance for various cancer indications.
About the IMpassion130 study
The IMpassion130 study is a phase III, multicenter, randomized, double-blind study evaluating the efficacy, safety and pharmacokinetics of Tecentriq plus nab-paclitaxel compared with placebo plus nab-paclitaxel in people with unresectable locally advanced or metastatic triple-negative breast cancer who have not received prior systemic therapy for metastatic breast cancer (mBC). For details of the study go to www.roche.com/.
Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1, which is expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the activation of T cells. Tecentriq is a cancer immunotherapy that has the potential to be used as a foundational combination partner with other immunotherapies, targeted medicines and various chemotherapies across a broad range of cancers. The development of Tecentriq and its clinical programme is based on our greater understanding of how the immune system interacts with tumours and how harnessing a person’s immune system combats cancer more effectively.
Tecentriq is approved in the US, EU and countries around the world, either alone or in combination with targeted therapies and/or chemotherapies in various forms of non-small cell and small cell lung cancer, certain types of metastatic urothelial cancer, and in PD-L1-positive triple-negative breast cancer.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the tenth consecutive year, Roche has been recognised as the most sustainable company in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,000 people worldwide. In 2018, Roche invested CHF 11 billion in R&D and posted sales of CHF 56.8 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
 Bray F, Ferlay J, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
 Eliyatkin N, Yalcin E, et al. Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. J Breast Health. 2015;11(2):59-66.
 This product is intended for in vitro diagnostic (IVD) use.
 VENTANA PD-L1 (SP142) Assay may not be available for some indications and/or cutoffs in all geographies.
 In Switzerland Tecentriq is approved for non-small cell lung cancer only.
 Abraxane® [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]
 Emens, et al. SABCS 2018 (Abstract GS1-04)
 The PD-L1 (SP142) Assay is proven to identify patients most likely to respond to treatment with Tecentriq, as demonstrated by higher overall response rates in Cohort 2 of the IMvigor 210 clinical trial. The novel approach uses immunohistochemistry (IHC) technology designed to visually enhance and score PD-L1 protein on tumour-infiltrating immune cells. In an analysis based on 14.4 months of median follow up, Tecentriq shrank tumours (ORR) in 15 percent (95% CI: 11, 19) of people evaluable for efficacy (n=310) whose disease progressed after platinum-based chemotherapy. Tecentriq shrank tumours in 26 percent (95% CI: 18, 36) of people whose disease had medium and high levels of PD-L1 expression (n=100).
Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: email@example.com
- Nicolas Dunant (Head)
- Patrick Barth
- Ulrike Engels-Lange
- Karsten Kleine
- Barbara von Schnurbein
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Change in Orion Group Executive Management Board as of 1 June 2020: Professor Outi Vaarala appointed as Senior Vice President for Research and Development25.5.2020 15:20:00 CEST | Press release
ORION CORPORATION STOCK EXCHANGE RELEASE 25 MAY 2020 AT 4.20 p.m. EEST Change in Orion Group Executive Management Board as of 1 June 2020: Professor Outi Vaarala appointed as Senior Vice President for Research and Development ProfessorOuti Vaarala, M.D., Ph.D. has been appointed Senior Vice President for Research and Development and member of the Executive Management Board of the Orion Group, as of 1 June 2020. Vaarala has held the position of Vice President, Oncology Research in Orion’s Research and Development as of 10 June 2019. Prior to Orion, Vaarala led drug discovery and development from target identification to clinical Phase 2 studies in Respiratory Inflammation and Autoimmunity therapy area, first at AstraZeneca, Sweden, and later at Medimmune/AstraZeneca, USA. Outi Vaarala is a medical doctor (University of Helsinki) and has a PhD in immunology. Outi Vaarala was appointed as a Professor of Pediatric Immunology, Linkoping University, Sweden, in 2000, and as a Professor of Aut
Auriant Mining:s delårsrapport för Q1 2020 och online-konferens den 29 maj 202025.5.2020 12:05:44 CEST | Pressemelding
Auriant Mining AB har nöjet att meddela att Bolagets delårsrapport för Q1 2020 kommer att publiceras på fredagen den 29 maj. Detta kommer att följas av en interaktiv webcast för analytiker och investerare med vd Sergey Ustimenko som kommer att presentera Auriant Mining:s resultat för Q1 2020 samt med en möjlighet att ställa frågor. Evenemanget börjar kl. 13:00 CET (13:00 Stockholm, 14:00 Moskva, 12:00 London). De som vill få en e-postpåminnelse en timme innan evenemanget kan registrera sig genom länken eller öppna följande länk direkt för att delta i online-konferensen fredagen den 29 maj: Link to register on Q1 2020 Interim Report Online Conference För mer information, vänligen kontakta: Sergey Ustimenko, VD Tel: +7 495 109 02 82 E-post: firstname.lastname@example.org Företagsnamn: Auriant Mining AB Kortnamn: AUR ISIN-kod: SE0001337213 Website: www.auriant.com www.facebook.com/AuriantMining/ Auriant Mining AB (AUR) är ett svenskt gruvbolag med inriktning på prospektering och guldprodukt
Auriant Mining Q1 2020 Interim Report and Online Conference, May 29th 202025.5.2020 12:05:44 CEST | Press release
Auriant Mining AB is pleased to announce that the Company’s Q1 2020 interim report will be published on Friday, May 29th. This will be followed by an interactive webcast for analysts and investors with the CEO, Sergey Ustimenko who will be presenting Auriant Mining’s Q1 2020 results as well as hosting a Q&A session. The event will begin at 13:00 CET (13:00 Stockholm, 14:00 Moscow, 12:00 London). Those who wish to receive an email reminder an hour before the event can pre-register using the link or open the link directly to participate in Online Conference on Friday, May 29th: Link to register on Q1 2020 Interim Report Online Conference For more information, please contact: Sergey Ustimenko, CEO Tel: +7 495 109 02 82 E-mail: email@example.com Company name: Auriant Mining AB Short name: AUR ISIN-code: SE0001337213 Website: www.auriant.com www.facebook.com/AuriantMining/ Auriant Mining AB (AUR) is a Swedish junior mining company focused on gold exploration and production in Rus
Result of SEK credit operation25.5.2020 11:45:00 CEST | Press release
RESULT OF SEK CREDIT OPERATION 2020-05-25 Auction date:2020-05-25Payment date:2020-05-25 (at 3 pm)Maturity date:2020-08-25Term:92 daysOffered volume:UnlimitedTotal bid amount:SEK 0.00 billionNumber of bids0Allotment:SEK 0.00 billionInterest rate: Repo rate + 0,20 percentage points
Ress Life Investments AS Half-Year Report – 1 October 2019 – 31 March 202025.5.2020 11:21:09 CEST | Press release
Corporate Announcement no. 20/2020: Half-Year Report 1 October 2019 – 31 March 2020 Copenhagen, 25 May 2020 The Board of Directors and Management have today discussed and approved the Half-Year Report of Ress Life Investments A/S for the period 1 October 2019 – 31 March 2020: Ress Life Investments A/S realised a net profit before and after tax of USD 3,638,925 for the period 1 October 2019 – 31 March 2020. The net profit for the period corresponds to a net return on equity of 1.99%, earnings per share at 40.60 and an increase in net asset value of USD 42.01 per share.The increase in profit before tax mainly relates to positive fair value adjustments offset by administrative expenses and staff costs.The fair value of the Company’s investment assets increased from USD 118,791,752 at 30 September 2019 to USD 159,631,723 at 31 March 2020.Equity stands at USD 182,699,386 as of 31 March 2020, corresponding to a net asset value of USD 1,960 per share compared with a net asset value of USD 1,9
Prosafe SE: Notice of Change to financial calendar25.5.2020 10:54:58 CEST | Press release
Due to a change in the timing of the Board meeting, the Q1 2020 results will be published on 26 May 2020 at about 01.30 p.m. CEST, which is one day earlier than originally announced. The Q1 2020 report and the Q1 2020 presentation will be published on www.newsweb.no and on Prosafe’s website www.prosafe.com Jesper Kragh Andresen, CEO and Stig H. Christiansen, Deputy CEO & CFO will on 27 May 2020 at 10:00 a.m. CEST host an audio webcast. The webcast can be followed at www.prosafe.com It will be possible to ask questions during the presentation by using the Q&A tool embedded in the audio webcast. A replay of the audio webcast will be made available at www.prosafe.com shortly after. Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to www.prosafe.com Stavanger, 25 May 2020 Prosafe SE For further information, please contact: Jesper K. Andresen, CEO Phone